Anticoagulation strategies and pulmonary safety in patients with active lung cancer and atrial fibrillation: A large-scale, competing risk analysis of 2000 patients.

The untreated cohort (12.7%) exhibited a 13.3% annual ischemic stroke rate.

In Inverse Probability of Treatment Weighting-adjusted analysis, Direct Oral Anticoagulants significantly reduced ischemic stroke risk compared to Vitamin K Antagonists (sHR: 0.42; 95% CI: 0.24-0.72; P = 0.002).

Squamous cell histology significantly interacted with Vitamin K Antagonists use, exacerbating pulmonary bleeding risk (P-interaction=0.002).